会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • PERICARDIAL THERAPEUTIC AND DIAGNOSTIC AGENT DELIVERY
    • PERICARDIAL治疗和诊断代理
    • WO1996039830A1
    • 1996-12-19
    • PCT/US1996007850
    • 1996-05-31
    • INDIANA UNIVERSITY FOUNDATION
    • INDIANA UNIVERSITY FOUNDATIONMARCH, Keith, L.ZIPES, Douglas, P.
    • A01N43/04
    • A61M25/0068A61B2017/00247A61B2018/00392A61K38/00A61K48/00A61M25/0082A61M2025/09183A61M2210/10A61M2210/122A61M2210/125C07K14/8125C12N2799/022A61M2230/005
    • A method for treating a patient's heart which comprises delivering a gene therapy agent into the pericardial sac around the patient's heart. The agent is introduced surgically or by transvascular means such as a catheter which has been introduced percutaneously or otherwise. Introducing the gene therapy agent into the pericardial sac contains the agent, allowing high concentration of the agent adjacent large regions of the epicardium and pericardium without spillage or systemic distribution to other organs or tissues. The gene therapy agents of this invention comprise vectors for transferring genetic information to the epicardial cells in vivo or harvested cells which have been genetically engineered in vitro. In a preferred embodiment, a catheter is percutaneously introduced, such as through the femoral artery, and guided upstream into the left ventricle. The distal end of the catheter advanced until it penetrates through the epicardium so that agent can be introduced into the pericardial space. Access to the pericardium may also be gained intraoperatively or through a thoracotomy. Additionally, the method may comprise employing a viscosity enhancer in conjunction with the gene therapy agent to affect the kinetics of the agent-host cell interaction and thus improve the rate and efficiency of transduction.
    • 一种治疗患者心脏的方法,其包括将基因治疗剂递送到患者心脏周围的心包囊内。 该药剂通过外科手术或经血管手段引入,例如经皮或其他方式导入的导管。 将基因治疗剂引入心包囊中含有该试剂,允许邻近心外膜和心包的大区域高剂量,而不会溢出或全身分布至其他器官或组织。 本发明的基因治疗剂包括用于将遗传信息转移到体外的心外膜细胞的载体或已在体外遗传工程化的收获的细胞。 在优选实施例中,导管例如通过股动脉经皮引入,并被引导到上游进入左心室。 导管的远端前进直到其穿透心外膜,使得药剂可以被引入心包空间。 也可以在手术中或通过胸廓切开术获得心包膜。 此外,该方法可以包括使用粘度增强剂与基因治疗剂联合以影响药物 - 宿主细胞相互作用的动力学,从而提高转导的速率和效率。